Jonatan Ising Bagger

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8700441/publications.pdf

Version: 2024-02-01

46 papers	1,917 citations	331538 21 h-index	265120 42 g-index
48 all docs	48 docs citations	48 times ranked	2650 citing authors

#	Article	IF	Citations
1	Impaired Regulation of the Incretin Effect in Patients with Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 737-745.	1.8	190
2	Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals. American Journal of Physiology - Renal Physiology, 2019, 316, G462-G472.	1.6	162
3	Increased Postprandial GIP and Glucagon Responses, But Unaltered GLP-1 Response after Intervention with Steroid Hormone, Relative Physical Inactivity, And High-Calorie Diet in Healthy Subjects. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 447-453.	1.8	152
4	The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes. American Journal of Physiology - Endocrinology and Metabolism, 2011, 300, E1038-E1046.	1.8	148
5	Evidence of Extrapancreatic Glucagon Secretion in Man. Diabetes, 2016, 65, 585-597.	0.3	136
6	Glucagon antagonism as a potential therapeutic target in type 2 diabetes. Diabetes, Obesity and Metabolism, 2011, 13, 965-971.	2.2	114
7	Glucagon and Type 2 Diabetes: the Return of the Alpha Cell. Current Diabetes Reports, 2014, 14, 555.	1.7	96
8	Glucose-Lowering Effects and Low Risk of Hypoglycemia in Patients With Maturity-Onset Diabetes of the Young When Treated With a GLP-1 Receptor Agonist: A Double-Blind, Randomized, Crossover Trial. Diabetes Care, 2014, 37, 1797-1805.	4.3	94
9	Reduced Glucose Tolerance and Insulin Resistance Induced by Steroid Treatment, Relative Physical Inactivity, and High-Calorie Diet Impairs the Incretin Effect in Healthy Subjects. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 3309-3317.	1.8	92
10	Effect of Oxyntomodulin, Glucagon, GLP-1, and Combined Glucagon +GLP-1 Infusion on Food Intake, Appetite, and Resting Energy Expenditure. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 4541-4552.	1.8	65
11	Impaired Incretin-Induced Amplification of Insulin Secretion after Glucose Homeostatic Dysregulation in Healthy Subjects. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 1363-1370.	1.8	61
12	Glucagon responses to increasing oral loads of glucose and corresponding isoglycaemic intravenous glucose infusions in patients with type 2 diabetes and healthy individuals. Diabetologia, 2014, 57, 1720-1725.	2.9	56
13	Glucagon Resistance at the Level of Amino Acid Turnover in Obese Subjects With Hepatic Steatosis. Diabetes, 2020, 69, 1090-1099.	0.3	50
14	The Alpha-Cell as Target for Type 2 Diabetes Therapy. Review of Diabetic Studies, 2011, 8, 369-381.	0.5	49
15	The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretionâ€"A Review. International Journal of Molecular Sciences, 2019, 20, 4092.	1.8	47
16	Incretin Effect and Glucagon Responses to Oral and Intravenous Glucose in Patients With Maturity-Onset Diabetes of the Young–Type 2 and Type 3. Diabetes, 2014, 63, 2838-2844.	0.3	43
17	Mechanisms of the Incretin Effect in Subjects with Normal Glucose Tolerance and Patients with Type 2 Diabetes. PLoS ONE, 2013, 8, e73154.	1.1	38
18	Reduced postprandial <scp>GLP</scp>â€1 responses in women with gestational diabetes mellitus. Diabetes, Obesity and Metabolism, 2013, 15, 713-720.	2.2	37

#	Article	IF	Citations
19	Diabetic Ketoacidosis in a Patient with Type 2 Diabetes After Initiation of Sodiumâ€“Glucose Cotransporter 2 Inhibitor Treatment. Basic and Clinical Pharmacology and Toxicology, 2016, 118, 168-170.	1.2	35
20	Amylin and Calcitonin: Potential Therapeutic Strategies to Reduce Body Weight and Liver Fat. Frontiers in Endocrinology, 2020, 11, 617400.	1.5	25
21	Involvement of steatosis-induced glucagon resistance in hyperglucagonaemia. Medical Hypotheses, 2016, 86, 100-103.	0.8	24
22	Determinants of Fasting Hyperglucagonemia in Patients with Type 2 Diabetes and Nondiabetic Control Subjects. Metabolic Syndrome and Related Disorders, 2018, 16, 530-536.	0.5	22
23	Impaired beta cell sensitivity to incretins in type 2 diabetes is insufficiently compensated by higher incretin response. Nutrition, Metabolism and Cardiovascular Diseases, 2017, 27, 1123-1129.	1.1	16
24	Hepatic microbiome in healthy lean and obese humans. JHEP Reports, 2021, 3, 100299.	2.6	15
25	Semimechanistic model describing gastric emptying and glucose absorption in healthy subjects and patients with type 2 diabetes. Journal of Clinical Pharmacology, 2016, 56, 340-348.	1.0	14
26	Women with prior gestational diabetes mellitus and prediabetes are characterised by a decreased incretin effect. Diabetologia, 2017, 60, 1344-1353.	2.9	14
27	One Yearâ€™s Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial. Journal of Clinical Medicine, 2020, 9, 3213.	1.0	14
28	Effects of Smoking Versus Nonsmoking on Postprandial Glucose Metabolism in Heavy Smokers Compared With Nonsmokers. Diabetes Care, 2018, 41, 1260-1267.	4.3	13
29	Higher Endogenous Glucose Production During OGTT vs Isoglycemic Intravenous Glucose Infusion. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 4377-4384.	1.8	12
30	Acute hypoglycemia and risk of cardiac arrhythmias in insulin-treated type 2 diabetes and controls. European Journal of Endocrinology, 2021, 185, 343-353.	1.9	12
31	Postprandial incretin and islet hormone responses and dipeptidyl-peptidase 4 enzymatic activity in patients with maturity onset diabetes of the young. European Journal of Endocrinology, 2015, 173, 205-215.	1.9	11
32	Glucagonostatic Potency of GLP-1 in Patients With Type 2 Diabetes, Patients With Type 1 Diabetes, and Healthy Control Subjects. Diabetes, 2021, 70, 1347-1356.	0.3	9
33	Therapy for Obesity Based on Gastrointestinal Hormones. Review of Diabetic Studies, 2011, 8, 339-347.	0.5	9
34	Mathematical Modelling of Glucoseâ€Dependent Insulinotropic Polypeptide and Glucagonâ€like Peptideâ€1 following Ingestion of Glucose. Basic and Clinical Pharmacology and Toxicology, 2017, 121, 290-297.	1.2	8
35	The effect of curcumin on hepatic fat content in individuals with obesity. Diabetes, Obesity and Metabolism, 2022, 24, 2192-2202.	2.2	8
36	Glucagon Clearance Is Preserved in Type 2 Diabetes. Diabetes, 2022, 71, 73-82.	0.3	6

#	Article	IF	Citations
37	THERAPY OF ENDOCRINE DISEASE: Amylin and calcitonin â€“ physiology and pharmacology. European Journal of Endocrinology, 2022, 186, R93-R111.	1.9	4
38	Is glucagonâ€like peptideâ€1 fully protected by the dipeptidyl peptidase 4 inhibitor sitagliptin when administered to patients with type 2 diabetes?. Diabetes, Obesity and Metabolism, 2018, 20, 1937-1943.	2.2	3
39	Circulating Levels of the Soluble Receptor for AGE (sRAGE) during Escalating Oral Glucose Dosages and Corresponding Isoglycaemic i.v. Glucose Infusions in Individuals with and without Type 2 Diabetes. Nutrients, 2020, 12, 2928.	1.7	2
40	Metabolic effects of 1-week binge drinking and fast food intake during Roskilde Festival in young healthy male adults. European Journal of Endocrinology, 2021, 185, 23-32.	1.9	2
41	No detectable effect of a type 2 diabetes-associated TCF7L2 genotype on the incretin effect. Endocrine Connections, 2020, 9, 1221-1232.	0.8	2
42	Glucagon Resistance at the Level of Amino Acid Turnover and Ureagenesis in Obese Subjects with Hepatic Steatosis. Diabetes, 2018, 67, 147-OR.	0.3	1
43	Clinical Features and Hepatic Molecular Characteristics in NAFLD and NASH Patients Compared to Normal Weight Healthy Individuals. Diabetes, 2018, 67, .	0.3	1
44	Physiological and pathophysiological aspects of incretin hormones and glucagon. Danish Medical Journal, 2017, 64, .	0.5	1
45	Mechanisms in Endocrinology: The physiology of neuronostatin. European Journal of Endocrinology, 2021, 185, R93-R101.	1.9	0
46	1721-P: Effect of the TCF7L2 Variant rs7903146 T Allele on the Incretin Effect in Individuals with Normal Glucose Tolerance or Type 2 Diabetes. Diabetes, 2019, 68, .	0.3	0